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discontinued the initially prescribed drug class, or had
another antihypertensive agent added for concurrent
therapy.
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Proportion of patients tested at least once. We
linked our cohort to the OHIP database to examine
laboratory testing patterns in the 6 months
immediately preceding their first antihypertensive
prescription (to define baseline testing patterns), and
in the first 24 months after the initial antihypertensive
dispensation (to define testing patterns during follow-
up). The OHIP database includes billing claims data for
laboratory tests performed in laboratories outside the
hospital setting.
14-16 We examined all claims for
laboratory monitoring of blood-based tests, and a
priori focused specifically on the 4 tests that were
recommended for all new hypertensive patients in the
Canadian national guidelines for all years of this study
— i.e., measurements of serum electrolytes, cholesterol,
glucose, and renal function. We defined "electrolyte
tests" as a measurement of serum sodium or
potassium; "cholesterol tests" as having total
cholesterol, low- or high-density lipoprotein
cholesterol, and/or triglycerides measured; "glucose
test" as having fasting or random blood glucose
measured; and "renal function tests" as having serum
creatinine or creatinine clearance measured.
We calculated the proportion of patients prescribed
each drug class who had each test done at least once
while they were on monotherapy. Associations between
drug class and whether laboratory tests were done at
least once were assessed in logistic regression models
comparing thiazides to newer agents with adjustment
for patient age, gender, Charlson co-morbidity score,
17
and baseline testing patterns (i.e., in the 6 months
before the initial antihypertensive prescription).
Patients treated with beta-blockers were excluded from
this analysis, since beta-blockers are not recommended
for initial monotherapy in elderly patients with
uncomplicated hypertension, and thus the question of
whether patients treated with beta-blockers received
more or less testing is moot.
8,18,19
Frequency and number of tests. To account for
varying lengths of time on antihypertensive
monotherapy, we calculated the test density for each
test per 6 months of monotherapy treatment (defined
as the number of tests performed per 100 patients
treated with monotherapy with that particular agent for
6 months). To compare results across drug classes, we
performed Poisson regression (with censoring at time
of hospital admission, death, discontinuation of
monotherapy, or switching of drug class) to compare
the frequency of testing between drug classes during
monotherapy after adjustment for age, gender, co-
morbidity, and testing in the 6 months before the initial
antihypertensive prescription.
All analyses were conducted using SAS version 8.02
(SAS Institute, Cary, NC).
Results
For the period July 1994 to March 2002 we identified
164,413 people over age 66 years who were newly
started on monotherapy with an antihypertensive drug,
and who did not have co-morbidities or indications
other than hypertension for that medication. Their
mean age was 73 years (standard deviation [SD] 6
years). In this cohort, 60,340 (37%) were male, and the
first-line antihypertensives prescribed were thiazides
(39%), ACE inhibitors (30%), calcium-channel blockers
(15%), beta-blockers (15%), and angiotensin receptor
blockers (1%)(Table 1). The duration of monotherapy
with the initially prescribed antihypertensive drug
ranged from a maximum of 24 months in 41,886
patients (25%) to less than 6 months in 81,002 patients
(49%). The mean duration of monotherapy with the
initially prescribed agent was 10.3 months.
Proportion of patients having tests done at least
once. Before their initial antihypertensive
prescription, patients prescribed newer agents were
more likely to have had laboratory tests done than
patients who were prescribed thiazides (Figure 1, all p
<0.0001). It should be noted, however, that 96,534
patients (59%) did not have any laboratory testing
done in the 6 months before their initial
antihypertensive prescription. After being prescribed
antihypertensive therapy, 79,985 of the cohort patients
(49%) had at least 1 laboratory test done at any point
during follow-up (50% of those who had testing done
before their initial prescription, and 48% of those who
did not have testing done before their initial
prescription).
In comparison with patients prescribed newer
agents, a greater proportion of patients prescribed
thiazides had their serum electrolytes measured at least
once during follow-up (38% v. 31%, odds ratio [OR]
1.38, 95% confidence interval [CI] 1.35–1.41, after
adjusting for age, gender, co-morbidity, and baseline
testing), but fewer thiazide-treated patients had any
monitoring of their renal function (41% v. 42%,
adjusted OR 0.95, 95% CI 0.93–0.97), serum glucose
(38% v. 40%, adjusted OR 0.90, 95% CI 0.88–0.92), or
cholesterol (24% v. 32%, adjusted OR 0.72, 95% CI
0.70–0.74)(Figure 1). As a result, the number of
patients who had at least one laboratory test performed
while on monotherapy with their initial
antihypertensive prescription did not differ between
thiazides and newer agents (49% v. 50%, adjusted OR
0.98, 95% CI 0.96–1.01).
Frequency and number of tests. During 1,701,520
months of monotherapy in this cohort of patients, the
most frequently performed laboratory tests were renal
function tests (77,052 every 6 months), serum glucose
(69,393 every 6 months), serum electrolytes (63,193
every 6 months), and cholesterol measurements
(47,115 every 6 months). Patients treated with thiazides
had more measurements of renal function, serumResearch McAlister et al
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electrolytes, or glucose during follow-up than patients
prescribed newer agents, but had less monitoring of
serum cholesterol levels (Table 2). These associations
were statistically significant on multivariate Poisson
regression analyses adjusting for age, gender, co-
morbidity, and baseline testing patterns (Table 3).
Magnitude of differences. Patients treated with
thiazide agents had 16 extra electrolyte tests, 6 extra
renal function tests, and 4 extra serum glucose tests
(but 6 fewer serum cholesterol tests) per 100 patients
every 6 months compared with patients prescribed
newer agents. The direct cost implications of the
laboratory testing profiles we observed in this
population-based cohort are, on a per-patient basis and
per 6 months, C$11.88 for thiazides and C$11.25 for
those treated with the newer drugs. In other words,
when considering laboratory testing costs only, the
choice of a thiazide for initial monotherapy in our
cohort of elderly patients with uncomplicated
hypertension resulted in an extra C$0.63 in laboratory
testing costs every 6 months.
Discussion
The frequency of laboratory testing in elderly patients
newly treated with antihypertensive agents was lower
than anticipated, given that the tests we focused on are
all recommended to be done as part of the initial
workup for newly diagnosed hypertensive patients.
8,20,21
At baseline, 59% of our cohort did not have any
laboratory testing done before initiation of
antihypertensive therapy and, over a mean follow-up of
10.3 months, less than half had any laboratory testing
done (and almost two-thirds did not have their serum
electrolytes or renal function monitored even once).
Patients prescribed thiazides were significantly more
likely to have their serum electrolytes, glucose, and
renal function monitored than patients prescribed any
of the newer drug classes, even after adjustment for
age, gender, co-morbidities and baseline testing before
the initial prescription. However, the magnitude of the
increase in laboratory testing frequency was small, and
the additional costs per patient of C$0.63 per 6 months
are substantially less than the acquisition costs for a 6-
month supply of ACE inhibitors (ranging between
C$126.79 and C$242.28 in the Ontario Drug Benefit
Plan, depending on the particular agent and dose
prescribed), angiotensin-receptor blockers (C$214.90
to C$230.74), or calcium-channel blockers (C$90.16 to
C$437.93) compared with thiazides ($14.13 for a 6-
month supply of 25 mg daily hydrochlorothiazide).
The distribution of antihypertensive drug classes
prescribed in our cohort of elderly patients, and the
fact that only one-quarter remained on initially
prescribed monotherapy for the entire 2-year follow-up
period in our study, are consistent with recently
published data from other locales.
22-25 Our finding that
many patients started on antihypertensive therapy do
not have guideline-recommended laboratory testing
done also confirms the results of previous studies
conducted in other settings, including a chart-based
audit conducted in one Canadian health region.
26-29 In
addition to reporting on a larger and population-based
sample from a different locale, we have extended these
earlier cross-sectional studies by reporting
longitudinally on a wider variety of tests in patients
treated with all the major antihypertensive drug
classes, and with adjustment for age, gender, co-
morbidity, and previous testing patterns. The lower
degree of laboratory monitoring we found compared
with these earlier studies is not unexpected, since our
cohort explicitly excluded patients with diabetes or
cardiac co-morbidities and patients treated with
multiple antihypertensive agents.
27,30
Study limitations. Although our study includes
complete information on prescribing and laboratory
testing for a large, representative, and population-
based sample of all adults aged 66 and over newly
treated with antihypertensive agents without co-
morbidities or indications other than hypertension,
and included 100% follow-up in Canada’s largest
province, there are some limitations. Many of these do
not affect the validity of our findings. For example,
although the use of antihypertensive prescriptions
without other indications to define cases of
hypertension is a relatively specific marker for the
condition, it will miss those patients who have not been
prescribed therapy. Yet, data for 1999–2002 from the
National Health and Nutrition Examination Survey
(NHANES) in the United States, and from the National
Public Health and Community Health Surveys in
Canada for 2000–2003 have shown that over 80% of
elderly people with recognized hypertension are
prescribed antihypertensive therapy.
31,32
Second, our study was limited to elderly people;
however, the prevalence of hypertension increases with
age, and more than half of all elderly people areResearch McAlister et al
Open Medicine 2007 1 (2):e60-e67
hypertensive.
33
Third, in creating our cohort we excluded patients
with diabetes or cardiac co-morbidities, and any
patients treated with more than one antihypertensive
agent; thus our cohort was undoubtedly a relatively
healthy group compared with many elderly
hypertensive populations. As a result, the testing
patterns we observed likely underestimate true testing
rates in elderly people with hypertension, as physicians
are likely to more closely follow laboratory parameters
in their sicker patients. However, restricting our cohort
to healthy patients enhances our ability to attribute
differences in testing patterns between drug classes to
those agents rather than to differing patterns of co-
morbidities in patients prescribed particular drug
classes.
Fourth, just as we have data only on patients who
fill their antihypertensive prescriptions, our laboratory
test data are also affected by patient compliance. To the
extent that some patients do not follow through with
recommended testing, our observed testing rates likely
underestimate physician test-ordering behaviour.
Fifth, a formal cost-effectiveness (or cost-
minimization) analysis would require incorporation of
the costs induced by testing (such as additional
diagnoses and physician visits, clinical events, and
indirect costs), which we did not capture; however, our
data do permit estimation of the direct costs for the
testing patterns we observed.
Sixth, we examined testing only within the first 24
months after a new antihypertensive prescription.
Previous studies have demonstrated that if testing is
done at all, it is usually done within the first month of a
new prescription.
28 Indeed, we did find that testing
frequency was highest in the first 90 days after
prescription and declined subsequently.
Some study limitations, however, could affect the
interpretation of our findings, and are unavoidable
given the datasets at our disposal. For example, we did
not have access to detailed clinical information such as
blood pressure levels or co-morbidities that are not
coded in administrative databases; and the reasons
why physicians chose to prescribe one drug over
another are not recorded in administrative data.
Although this does not directly affect our question of
interest (whether laboratory testing patterns differ
across antihypertensive drug classes), it does prevent
the classification of the "appropriateness" of the
observed testing patterns. As co-morbidities may
influence the choice of antihypertensive agent and the
frequency of laboratory monitoring, the influence of
these unmeasured confounders on our findings are
unknown. However, as thiazide-treated patients were
older and had higher Charlson scores, it is not
unreasonable to speculate that these unmeasured
confounders would bias toward higher test frequency in
thiazide-treated patients. So, although the magnitude
of this bias is impossible to ascertain in this data set, it
is reassuring that the direction of this bias actually
serves to strengthen our conclusion that the use of
thiazides did not induce a marked increase in
laboratory testing.
Second, we censored follow-up at the time patients
were switched from antihypertensive monotherapy,
admitted to hospital, or died, and calculated test
densities with each drug class to adjust for varying
lengths of follow-up. Thus, while randomized trials
suggest little difference between drug classes in these
outcomes (and randomized trials would be the most
appropriate design to detect such differences), it
should be acknowledged that any differential censoring
(if, for example, one drug class caused excess hospital
admissions compared with the other agents) could
have influenced our results by spuriously reducing the
apparent association between that drug class and
laboratory testing (or spuriously increasing the
apparent association if hospital admission were
preceded by an increasing pattern of testing).
Third, the OHIP database records only those tests
done at community (i.e., not hospital-based)
laboratories and those paid from OHIP funds.
However, our study focused only on outpatients, and
76% of all outpatient laboratory tests in Ontario are
captured in these databases.
14,15 It seems unlikely that
patients treated with one particular drug class would
be more (or less) likely to get their tests done in a
hospital laboratory or a private laboratory versus a
publicly funded community laboratory.
Fourth, we have neither examined nor adjusted for
any potential changes in laboratory testing patterns
over the 8-year duration of this study. Although the
question of whether laboratory utilization in Ontario
has changed over the past decade is an interesting one,
it would be best answered with a larger data set and
controlling for ordering/prescribing physician, system-
level factors (particularly since health care
restructuring was operant at that time), as well as
patient-level variables.
Fifth, it is not possible with administrative claims
databases to definitely attribute causation (i.e., that
conducting the observed tests was specifically due to
the therapy prescribed), but merely association (i.e.,
that certain test ordering patterns are associated with
particular drug classes).
Finally, because we are unable to link the
prescribing physician with the laboratory and drug
benefit databases, we cannot adjust for the prescribing
physician as a possible confounder of the association
between antihypertensives and test frequency.
Although the fact that there are over 28,000 physicians
practising in Ontario implies that the impact of a
handful of physicians is likely to be negligible on our
results, future studies should investigate whether
clinicians who frequently order laboratory tests differResearch McAlister et al
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in their prescribing behaviours from those that order
fewer tests.
It must be recognized that our study is a description
of current patterns of practice as they relate to testing;
whether or not frequency of "appropriate" testing
actually improves hypertension-related health
outcomes is not something that has yet been answered
in the literature, nor was our study designed to address
this issue. Indeed, none of the plethora of large
randomized trials of antihypertensive agents published
in the past decade is able to answer this question
because many trial participants withdrew from therapy
and the majority of trial patients were treated with
multiple drugs. Both of these facts make it difficult to
attribute laboratory abnormalities, and the timing of
their detection, to the initially allocated drug(s). As a
result, current recommendations for the frequency with
which to monitor laboratory tests in patients
prescribed antihypertensive therapies are largely
subjective and are based on expert opinion with little
empirical evidence to support either appropriateness
or cost-effectiveness. There is clearly a need for better
research to inform future recommendations for
laboratory monitoring based on the frequency, severity
and timing of abnormalities seen when particular
therapies are used in clinical practice.
In conclusion, we found that in a cohort of elderly
patients newly treated with antihypertensive drugs and
without non-blood pressure lowering indications or
cardiac co-morbidities, laboratory testing before and
after their first prescription was infrequent. Although
those initially treated with thiazides had laboratory
tests performed more frequently, the magnitude of the
increase was small. As a result, although the costs for